Exercise and GLP-1 medications

Activity is part of the approved use

The indications for Wegovy® injection and tablets, Zepbound®, Saxenda® and Foundayo™ share the same frame: each medicine is used together with a reduced-calorie diet and increased physical activity ^[1][2][3][4]. The weight results in these labels were reached with medicine plus lifestyle change, not with medicine alone.

The NIDDK, part of the US National Institutes of Health, puts it plainly: weight management medicines do not take the place of physical activity or healthy eating, and studies show they work best within a lifestyle programme ^[9].

What trial participants were asked to do

In Wegovy® Studies 2, 3, 5, 7, 8 and 9, everyone was counselled to increase physical activity with a recommended minimum of 150 minutes a week, from the first dose of medicine or placebo until the trial ended. Study 4 used a more intensive programme, starting at 100 minutes a week and building gradually to 200 ^[1]. The Saxenda® and Foundayo™ trials used the same 150-minute counselling ^[3][4].

The Zepbound® label describes one trial that began with lifestyle change before any medicine. In Study 3, adults spent 12 weeks in an intensive programme with a dietitian, including instruction to exercise for at least 150 minutes a week; only those who lost at least 5% in that period went on to be randomised, and their average loss from lifestyle alone was 6.9% ^[2]. Because placebo groups in all these trials received the same advice, the gap between groups reflects the medicine added to that advice.

One trial tested exercise and a GLP-1 medicine side by side

The S-LITE trial in Copenhagen is one of the few randomised studies built to separate the two. Adults with obesity and without diabetes first lost an average of 13.1 kg on an 8-week low-calorie diet. The 195 participants were then assigned for a year to supervised moderate-to-vigorous exercise with placebo, liraglutide 3.0 mg a day (the Saxenda® maintenance dose) with usual activity, both together, or placebo with usual activity ^[12].

After a year, every active strategy kept off more weight than placebo: by 4.1 kg with exercise, 6.8 kg with liraglutide and 9.5 kg with the combination. The combination lowered body-fat percentage by 3.9 points, roughly double either single strategy, and it was the only arm linked with better HbA1c, insulin sensitivity and cardiorespiratory fitness ^[12].

A follow-up one year after treatment ended, attended by 109 participants, found that those who had exercised regained less than those who had stopped liraglutide alone ^[13]. Limits matter here: one trial, one centre, liraglutide rather than semaglutide or tirzepatide, a maintenance setting after a diet, and supervised training that most people do not have. It shows the two can add up; it does not set a programme for you.

What the US guidelines set out for adults

• At least 150 to 300 minutes a week of moderate-intensity aerobic activity, such as brisk walking or fast dancing ^[7].
• Muscle-strengthening activity, such as lifting weights or push-ups, on at least 2 days a week ^[7].
• Move more and sit less: the guidelines link more sedentary time with higher risk of heart disease, high blood pressure and death from any cause ^[7].
• Any amount counts. The second edition dropped the earlier rule that only bouts of 10 minutes or longer counted ^[7].
• Some benefits begin straight away, including lower anxiety and blood pressure and better sleep and insulin sensitivity ^[7].
• On 9 October 2026, HHS asked for public comments to help write new guidance on step counts and muscle-strengthening activity, which will add to the current second edition ^[8].

Label warnings to know before a workout, brand by brand

None of these warnings is about exercise as such; they describe effects that can show up as dizziness, a racing pulse or weakness during activity. The figures are from each label’s own trials and are not comparisons between medicines.

Fluids, kidneys and the days with stomach symptoms

Every label in the table carries a warning about acute kidney injury after fluid loss, mostly in people who had nausea, vomiting or diarrhea, and asks for kidney function to be checked in people with such reactions, especially while the dose is being started or raised ^{[1][2][3][4][5][6]}. The Wegovy® Medication Guide says it is important to drink fluids to lower the chance of dehydration and to tell your healthcare provider straight away about vomiting or diarrhea that will not settle ^[1].

A hard session on a day of vomiting or very little food is the kind of situation those warnings describe. How to adjust your training around such days is a question for your clinician; the labels set no rule for it.

If you have type 2 diabetes

• MedlinePlus asks people with diabetes to have their provider confirm that an exercise programme is safe before starting, and notes that medicines that lower blood sugar can make it drop too low during exercise ^[10].
• It describes checking blood sugar before and after exercise, and during longer or unfamiliar sessions, because levels can keep falling for up to 12 hours afterwards ^[10].
• It also suggests keeping a fast-acting source of sugar with you and telling the people you train with that you have diabetes ^[10].
• People with diabetic eye disease are asked to have an eye exam before starting vigorous exercise, because heavy lifting in particular can make it worse ^[10]. The Ozempic® and Mounjaro® labels separately ask for monitoring of people with a history of diabetic retinopathy ^[5][6].
• The MedlinePlus semaglutide page asks you to check with your doctor what to do when your diet, exercise or weight changes a lot, since each can shift blood sugar ^[11].

Fat mass, lean mass and how you move

The Wegovy® and Zepbound® labels say that, of the weight these medicines take off, fat mass makes up more than lean mass ^[1][2]. That is a comparison, not a statement that lean mass is untouched; the article on lean mass in GLP-1 trials covers the body-scan numbers.

On how people felt and moved, the STEP 1 trial of semaglutide 2.4 mg reported a larger rise in participant-reported physical functioning than placebo over 68 weeks ^[14], and the European Wegovy® document describes the improvement in physical functioning scores as small ^[16]. These are questionnaire results for groups, not a forecast for your own fitness.

Habits that outlast the prescription

The NIDDK says you will probably regain some weight after stopping a weight management medicine, and that healthy eating and more activity may help you regain less or keep it off. It adds that some people may need more than 300 minutes of moderate activity a week to reach or maintain a weight-loss goal ^[9].

Because obesity is a chronic disease, the NIDDK says new eating and activity habits may need to last for years, perhaps for life ^[9]. The S-LITE follow-up points the same way within its limits: the people who had trained kept more of their result a year after treatment stopped ^[13]. Our article on weight plateaus looks at what the long trials measured over time.

Wegovy®, Saxenda® and Ozempic® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.